Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
30 July 2021Website:
http://maxcyte.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:29:13 GMTDividend
Analysts recommendations
Institutional Ownership
MXCT Latest News
MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT.
Legend Biotech obtains license to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells. Legend Biotech obtains license to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.
MaxCyte, Inc., a company specializing in cell-engineering technologies, will announce its first quarter 2024 financial results on May 7th, 2024 after the U.S. market closes. A conference call with company management to discuss the results will take place at 4:30 p.m. Eastern Time.
MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
MaxCyte is a pick-and-shovel play on cell editing technology, but may capture a royalty stream from successful products. Vertex's potential candidate approval in the U.S. could prove a decisive catalyst ultimately validating MaxCyte's approach and business model. If MaxCyte's partners see commercial success, MaxCyte could be valued at multiples of its current price on potential royalties.
MaxCyte, Inc. (NASDAQ:MXCT ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Sean Menarguez - Head of IR Doug Doerfler - President & CEO Douglas Swirsky - CFO Conference Call Participants Dan Arias - Stiefel Hannah Hefley - Stephens Matt Larew - William Blair Steven Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to MaxCyte's Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced Company management will participate at two upcoming investor conferences.
MaxCyte (NASDAQ: MXCT ) stock is sliding lower on Thursday following the release of preliminary earnings data for Q3. The bad news for investors in MXCT stock comes from its new Q3 revenue guidance of $7.8 million to $8 million.
What type of business is MaxCyte?
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
What sector is MaxCyte in?
MaxCyte is in the Healthcare sector
What industry is MaxCyte in?
MaxCyte is in the Medical Devices industry
What country is MaxCyte from?
MaxCyte is headquartered in United States
When did MaxCyte go public?
MaxCyte initial public offering (IPO) was on 30 July 2021
What is MaxCyte website?
https://maxcyte.com
Is MaxCyte in the S&P 500?
No, MaxCyte is not included in the S&P 500 index
Is MaxCyte in the NASDAQ 100?
No, MaxCyte is not included in the NASDAQ 100 index
Is MaxCyte in the Dow Jones?
No, MaxCyte is not included in the Dow Jones index
When does MaxCyte report earnings?
The next expected earnings date for MaxCyte is 09 August 2024